Showing 1672 results
-
Press release /Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be…
-
Press release /First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal…
-
Press release /HER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…
-
Press release /Strong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
-
Press release /In a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global…
-
Press release /Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced…
-
Press release /In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
-
Press release /Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces…
-
Press release /Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the…
-
Press release /Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to…